BRISTOL MYERS SQUIBB CO

BRISTOL MYERS SQUIBB CO (BMY) — Investment Memo

🐂 The Bull Case (Warren's voice)

• The Legal Monopoly: This isn't a consumer preference game; it's a regulatory mandate. When BMY owns the patent for a life-sustaining molecule, they don't have "customers"—they have captives. That is the purest form of a moat.
• The "Accounting Fog" Advantage: Wall Street is obsessed with the P&L, which is currently a disaster of impairments and restructuring. But cash doesn't lie. The massive divergence between NI (-$8.9B) and FCF ($13.9B) suggests the market is pricing this as a failing business while the cash register is actually ringing loudly.
• Mispriced Cash Cow: If you strip away the GAAP noise, you have a machine generating double-digit billions in free cash flow. If the market continues to punish them for "innovation deficits," we get to buy a high-margin toll bridge at a discount.
• Attractiveness: This becomes a Berkshire-grade investment when the price reflects a stagnant business, but we are paid to wait while the current patent portfolio continues to print money.

🐻 The Bear Case (Charlie inverts)

• The Patent Cliff (The Guillotine): The "moat" is a timer. Once the patent expires on Eliquis or Opdivo, the revenue doesn't just decline—it evaporates. A monopoly with an expiration date is just a countdown to irrelevance.
• The M&A Treadmill: They are buying growth (Karuna, Rayze, Mirati) because they can't grow organically. This is the "Imperial Pharma" trap: spending billions to buy hopes and dreams to replace lost revenue, often overpaying in the process.
• The Debt Anchor: Moving from $5.7B to $44.8B in debt is a reckless expansion of the balance sheet. In a world of higher-for-longer rates, that debt service eats the very FCF the bulls are praising.
• The Most Likely Killer: The combination of the Inflation Reduction Act (government price caps) and the Patent Cliff. This is a structural pincer movement that permanently lowers the ceiling on pharma margins. Timeframe: 3–7 years.

💰 Valuation & Margin of Safety

The provided DCF assumes a 15% FCF growth rate—which is aggressively optimistic for a company facing patent losses and heavy debt. We must treat this value as a "best-case" ceiling.

• Intrinsic value estimate: $225.96 per share
• 25% margin of safety entry: $169.47 (Still likely overpaying given the risk profile)
• 50% margin of safety entry: $112.98 (The "Buffett Ideal" for a risky pharma play)
• Current Status: Deeply Cheap relative to the DCF, but Dangerously Priced relative to the structural decay. The gap exists because the market doesn't believe in the 15% growth rate.

Verdict: WATCH

The distance between the current market price and the DCF is seductive, but the 15% growth assumption is a hallucination. We will wait for the debt to trend downward or for one of the recent acquisitions to show a clear, non-speculative path to replacing the patent cliff revenue. We don't buy "cigar butts" that are currently on fire.